

Subpopulation	Model	1-year cohort		5-year cohort	
		AUROC (95% CI)	AUCPR (95% CI)	AUROC (95% CI)	AUCPR (95% CI)
Complete PCE data (1y n=313, % IHD positive=4.5) / (5y n=72, % IHD positive=26.4)	FRS	.71 (.58-.82)	.09 (.07-.17)	.54 (.40-.65)	.28 (.24-.39)
	PCE	<b>.75 (.61-.85)</b>	<b>.17 (.09-.37)</b>	.60 (.46-.70)	.31 (.27-.43)
	Segmentation only	.67 (.55-.76)	.07 (.06-.11)	.56 (.42-.69)	.33 (.26-.50)
	PCE+Segmentation	.73 (.58-.85)	.12 (.08-.20)	.56 (.42-.68)	.31 (.26-.44)
	Clinical only	.63 (.51-.76)	.07 (.05-.14)	.78 (.66-.87)	.61 (.46-.79)
	Imaging only	.69 (.59-.82)	.09 (.06-.18)	.71 (.58-.80)	.51 (.37-.66)
	Imaging+Clinical Fusion	.67 (.57-.79)	.08 (.06-.17)	.79 (.67-.87)	.62 (.49-.78)
	Imaging+Clinical+Segmentation Fusion	.64 (.55-.77)	.08 (.05-.17)	<b>.81 (.69-.89)</b>	<b>.64 (.50-.81)</b>
Missing PCE data (1y n=1305, % IHD positive=4.4) / (5y n=282, % IHD positive=24.8)	FRS	.72 (.67-.77)	.09 (.07-.13)	.76 (.70-.81)	.49 (.41-.58)
	PCE	.75 (.71-.81)	.12 (.10-.18)	.77 (.72-.82)	.48 (.41-.57)
	Segmentation	.70 (.65-.75)	.08 (.07-.11)	.77 (.72-.82)	.46 (.40-.56)
	PCE+Segmentation	.77 (.73-.82)	.12 (.09-.17)	.79 (.74-.83)	.48 (.41-.58)
	Clinical only	<b>.80 (.76-.84)</b>	.16 (.12-.24)	.86 (.81-.89)	.67 (.60-.75)
	Imaging only	.75 (.71-.80)	.11 (.09-.16)	.83 (.78-.87)	.69 (.61-.77)
	Imaging+Clinical Fusion	.79 (.75-.84)	<b>.17 (.12-.24)</b>	<b>.88 (.84-.91)</b>	<b>.73 (.66-.81)</b>
	Imaging+Clinical+Segmentation Fusion	.77 (.72-.82)	<b>.17 (.12-.24)</b>	.87 (.83-.91)	.72 (.65-.80)
40-75 y/o (1y n=1047, % IHD positive=4.5) / (5y n=241, % IHD positive=27.8)	FRS	.63 (.57-.69)	.07 (.05-.09)	.66 (.59-.72)	.39 (.34-.47)
	PCE	.69 (.62-.75)	.08 (.07-.11)	.70 (.64-.76)	.43 (.37-.52)
	Segmentation	.67 (.61-.72)	.07 (.06-.10)	.68 (.62-.74)	.40 (.35-.49)
	PCE+Segmentation	.71 (.64-.76)	.10 (.08-.15)	.70 (.64-.76)	.41 (.36-.50)
	Clinical only	.70 (.64-.77)	.11 (.08-.17)	.84 (.79-.88)	.68 (.60-.77)
	Imaging only	.70 (.65-.77)	.10 (.08-.17)	.77 (.71-.82)	.63 (.56-.72)
	Imaging+Clinical Fusion	<b>.73 (.68-.80)</b>	<b>.13 (.09-.20)</b>	<b>.86 (.82-.90)</b>	<b>.73 (.66-.81)</b>
	Imaging+Clinical+Segmentation Fusion	.70 (.64-.78)	.12 (.09-.20)	.85 (.81-.89)	<b>.73 (.65-.81)</b>
Under 40 y/o (1y n=450, % IHD positive=1.1) / (5y n=81, % IHD positive=8.6)	FRS	.35 (.10-.38)	.01 (.01-.02)	.64 (.32-.83)	.29 (.12-.61)
	PCE	.46 (.12-.64)	.01 (.01-.02)	.76 (.59-.86)	.20 (.14-.43)
	Segmentation	.65 (.33-.84)	<b>.05 (.01-.19)</b>	.59 (.19-.84)	.32 (.12-.61)
	PCE+Segmentation	.56 (.23-.69)	<b>.05 (.01-.22)</b>	.70 (.39-.90)	.28 (.14-.60)
	Clinical only	<b>.69 (.29-.94)</b>	<b>.05 (.02-.15)</b>	.76 (.44-.95)	.40 (.20-.69)
	Imaging only	<b>.69 (.41-.94)</b>	.03 (.02-.08)	<b>.82 (.54-.97)</b>	.47 (.28-.84)

	Imaging+Clinical Fusion	<b>.69 (.33-.94)</b>	.04 (.02-.10)	.80 (.52-.97)	.51 (.27-.81)
	Imaging+Clinical+Segmentation Fusion	.68 (.43-.90)	.03 (.02-.07)	.80 (.49-.98)	<b>.55 (.31-.86)</b>
	FRS	.47 (.33-.56)	.15 (.13-.22)	.51 (.36-.70)	.55 (.43-.73)
	PCE	.51 (.35-.61)	.19 (.14-.34)	.36 (.22-.55)	.40 (.36-.53)
Over 75 y/o (1y n=121, % IHD positive=15.7) / (5y n=32, % IHD positive=46.9)	Segmentation	.43 (.30-.54)	.15 (.13-.24)	.64 (.45-.79)	.65 (.52-.82)
	PCE+Segmentation	.54 (.39-.65)	.19 (.15-.27)	.49 (.30-.65)	.49 (.40-.68)
	Clinical only	<b>.58 (.44-.68)</b>	<b>.22 (.17-.36)</b>	.61 (.42-.77)	.66 (.52-.80)
	Imaging only	.50 (.38-.63)	.17 (.14-.28)	<b>.76 (.61-.89)</b>	<b>.78 (.66-.89)</b>
	Imaging+Clinical Fusion	.54 (.39-.65)	.20 (.15-.33)	.70 (.52-.84)	.75 (.62-.88)
	Imaging+Clinical+Segmentation Fusion	.56 (.40-.67)	<b>.22 (.16-.37)</b>	.67 (.49-.82)	.72 (.59-.85)
	FRS	.70 (.65-.77)	.11 (.08-.17)	.73 (.66-.81)	.48 (.41-.60)
	PCE	.74 (.69-.82)	<b>.15 (.11-.24)</b>	.73 (.64-.80)	.47 (.40-.60)
Male (1y n=684, % IHD positive=5.4) / (5y n=125, % IHD positive=30.4)	Segmentation	.69 (.62-.74)	.09 (.08-.13)	.71 (.62-.78)	.46 (.39-.60)
	PCE+Segmentation	.73 (.67-.80)	.12 (.09-.18)	.74 (.65-.81)	.49 (.41-.61)
	Clinical only	<b>.76 (.71-.81)</b>	.13 (.10-.21)	.82 (.75-.88)	.69 (.60-.80)
	Imaging only	.72 (.66-.78)	.11 (.09-.18)	.84 (.77-.90)	.74 (.64-.83)
	Imaging+Clinical Fusion	.75 (.70-.81)	.14 (.10-.23)	<b>.88 (.82-.93)</b>	<b>.76 (.67-.85)</b>
	Imaging+Clinical+Segmentation Fusion	.72 (.67-.80)	<b>.15 (.11-.24)</b>	<b>.88 (.82-.92)</b>	.75 (.66-.85)
	FRS	.76 (.69-.82)	.09 (.07-.15)	.73 (.66-.79)	.39 (.33-.50)
	PCE	.75 (.67-.82)	.11 (.08-.19)	.73 (.67-.79)	.38 (.32-.48)
Female (1y n=934, % IHD positive=3.6) / (5y n=229, % IHD positive=22.3)	Segmentation	.73 (.66-.79)	.08 (.06-.12)	.73 (.66-.79)	.42 (.34-.53)
	PCE+Segmentation	<b>.78 (.70-.85)</b>	.12 (.09-.18)	.74 (.68-.80)	.40 (.33-.50)
	Clinical only	.75 (.67-.81)	.12 (.08-.20)	.84 (.78-.89)	.62 (.53-.72)
	Imaging only	.75 (.68-.81)	.10 (.07-.19)	.78 (.71-.84)	.57 (.48-.67)
	Imaging+Clinical Fusion	.77 (.69-.83)	<b>.13 (.09-.22)</b>	<b>.85 (.79-.90)</b>	.65 (.56-.75)
	Imaging+Clinical+Segmentation Fusion	.74 (.66-.81)	.12 (.09-.21)	.84 (.79-.89)	<b>.66 (.57-.75)</b>
	FRS	.73 (.64-.81)	.08 (.07-.14)	.73 (.62-.86)	.59 (.46-.75)
	PCE	<b>.82 (.74-.89)</b>	.15 (.10-.34)	<b>.78 (.66-.89)</b>	<b>.66 (.52-.81)</b>
Asian (1y n=257, % IHD positive=4.3) / (5y n=55, % IHD positive=32.7)	Segmentation	.65 (.56-.74)	.06 (.05-.10)	.77 (.65-.89)	.64 (.51-.81)
	PCE+Segmentation	.80 (.72-.87)	.11 (.08-.19)	.76 (.64-.88)	.61 (.48-.78)
	Clinical only	.81 (.73-.88)	.14 (.10-.29)	.72 (.60-.84)	.56 (.43-.74)
	Imaging only	.76 (.66-.85)	.11 (.08-.21)	.76 (.64-.90)	.72 (.60-.85)

	Imaging+Clinical Fusion	.81 (.74-.88)	.15 (.10-.35)	.75 (.63-.88)	<b>.66 (.53-.81)</b>
	Imaging+Clinical+Segmentation Fusion	.81 (.74-.88)	<b>.18 (.10-.38)</b>	.74 (.63-.86)	.62 (.48-.77)
	FRS	.92 (.88-.98)	.23 (.15-.50)	.77 (.25-1.00)	.77 (.50-1.00)
	PCE	.83 (.75-.93)	.12 (.09-.25)	.73 (.36-1.00)	.66 (.32-1.00)
Non-Hispanic Black (1y n=64, % IHD positive=3.1)/ (5y n=13, % IHD positive=23.1)	Segmentation	<b>.97 (.92-1.00)</b>	<b>.42 (.27-1.00)</b>	.73 (.36-1.00)	.66 (.31-1.00)
	PCE+Segmentation	.94 (.88-.98)	.33 (.22-.67)	.97 (.83-1.00)	.92 (.73-1.00)
	Clinical only	.76 (.53-.97)	.14 (.06-.50)	.93 (.75-1.00)	.81 (.53-1.00)
	Imaging only	.94 (.89-.98)	.29 (.19-.67)	.70 (.17-1.00)	.65 (.29-1.00)
	Imaging+Clinical Fusion	.90 (.85-.97)	.18 (.13-.40)	.93 (.75-1.00)	.87 (.67-1.00)
	Imaging+Clinical+Segmentation Fusion	.83 (.74-.94)	.12 (.09-.29)	<b>1.00 (1.00-1.00)</b>	<b>1.00 (1.00-1.00)</b>
	FRS	.74 (.61-.86)	<b>.18 (.10-.37)</b>	.83 (.74-.92)	.68 (.55-.83)
	PCE	.71 (.58-.82)	<b>.18 (.09-.38)</b>	.87 (.79-.94)	.67 (.55-.83)
Hispanic (1y n=306, % IHD positive=4.9)/ (5y n=79, % IHD positive=27.8)	Segmentation	.68 (.57-.79)	.11 (.07-.23)	.78 (.69-.86)	.52 (.41-.67)
	PCE+Segmentation	.77 (.68-.85)	.14 (.10-.25)	.83 (.75-.91)	.61 (.49-.77)
	Clinical only	<b>.77 (.70-.84)</b>	.11 (.09-.19)	<b>.90 (.80-.97)</b>	<b>.83 (.72-.93)</b>
	Imaging only	.71 (.60-.80)	.11 (.07-.21)	.78 (.69-.87)	.56 (.44-.71)
	Imaging+Clinical Fusion	.73 (.64-.82)	.13 (.08-.29)	.89 (.81-.95)	.80 (.69-.90)
	Imaging+Clinical+Segmentation Fusion	.70 (.60-.80)	.12 (.08-.28)	.87 (.78-.95)	.78 (.66-.89)
	FRS	.65 (.58-.73)	.06 (.05-.08)	.43 (.27-.61)	.23 (.21-.35)
	PCE	<b>.81 (.66-.92)</b>	.12 (.08-.26)	.46 (.29-.63)	.24 (.21-.37)
Other (1y n=189, % IHD positive=3.7) / (5y n=32, % IHD positive=25.0)	Segmentation	.60 (.46-.74)	.05 (.04-.08)	.69 (.53-.86)	.42 (.31-.70)
	PCE+Segmentation	.72 (.61-.82)	.08 (.06-.13)	.48 (.32-.64)	.24 (.22-.36)
	Clinical only	.77 (.63-.89)	.12 (.07-.30)	.64 (.41-.81)	.53 (.33-.76)
	Imaging only	.78 (.68-.88)	.09 (.07-.18)	<b>.90 (.74-1.00)</b>	<b>.86 (.70-1.00)</b>
	Imaging+Clinical Fusion	<b>.81 (.69-.91)</b>	.12 (.08-.25)	.77 (.58-.90)	.63 (.43-.84)
	Imaging+Clinical+Segmentation Fusion	.80 (.62-.93)	<b>.14 (.09-.29)</b>	.75 (.54-.91)	.65 (.45-.86)
	FRS	.69 (.64-.77)	.10 (.07-.18)	.70 (.62-.76)	.32 (.27-.42)
Non-Hispanic White (1y n=802, % IHD positive=4.5) / (5y n=175, % IHD positive=21.7)	PCE	.75 (.70-.83)	.13 (.09-.22)	.70 (.62-.77)	.34 (.29-.45)
	Segmentation	.72 (.66-.78)	.09 (.07-.13)	.68 (.59-.75)	.35 (.29-.47)
	PCE+Segmentation	.75 (.69-.83)	.15 (.11-.24)	.72 (.64-.79)	.36 (.31-.49)
	Clinical only	.75 (.69-.83)	.18 (.11-.29)	.85 (.79-.90)	.62 (.51-.73)

	Imaging only	.73 (.66-.80)	.14 (.09-.23)	.85 (.79-.90)	.65 (.55-.76)
	Imaging+Clinical Fusion	<b>.77 (.70-.84)</b>	<b>.19 (.13-.31)</b>	<b>.90 (.85-.93)</b>	.69 (.59-.80)
	Imaging+Clinical+Segmentation Fusion	.73 (.65-.81)	<b>.19 (.12-.31)</b>	<b>.90 (.85-.94)</b>	<b>.72 (.63-.83)</b>
	FRS	.72 (.65-.79)	.14 (.12-.20)	.69 (.60-.77)	.50 (.43-.62)
Taking lipid modifying agents (1y n=375, % IHD positive=7.7) / (5y n=105, % IHD positive=37.1)	PCE	.72 (.66-.80)	.17 (.13-.26)	.70 (.62-.78)	.50 (.43-.61)
	Segmentation	.65 (.59-.72)	.11 (.09-.17)	.66 (.57-.75)	.53 (.44-.65)
	PCE+Segmentation	<b>.76 (.68-.82)</b>	.18 (.14-.24)	.71 (.63-.79)	.50 (.44-.63)
	Clinical only	.73 (.64-.80)	.19 (.14-.30)	.85 (.78-.91)	.79 (.71-.88)
	Imaging only	.71 (.63-.80)	.16 (.12-.25)	.83 (.75-.90)	.79 (.71-.86)
	Imaging+Clinical Fusion	<b>.76 (.68-.83)</b>	<b>.22 (.16-.35)</b>	.88 (.81-.93)	.83 (.76-.91)
	Imaging+Clinical+Segmentation Fusion	.74 (.64-.82)	<b>.22 (.16-.35)</b>	<b>.89 (.82-.94)</b>	<b>.86 (.79-.92)</b>
	FRS	.67 (.61-.74)	.06 (.05-.11)	.69 (.62-.75)	.31 (.27-.40)
Not taking lipid modifying agents (1y n=1243, % IHD positive=3.4) / (5y n=249, % IHD positive=20.1)	PCE	.73 (.68-.81)	<b>.10 (.07-.18)</b>	.72 (.65-.77)	.33 (.29-.43)
	Segmentation	.69 (.62-.75)	.06 (.05-.09)	.73 (.66-.79)	.37 (.31-.48)
	PCE+Segmentation	.73 (.67-.79)	.08 (.06-.11)	.73 (.66-.78)	.36 (.29-.45)
	Clinical only	.75 (.70-.81)	.08 (.07-.12)	.83 (.77-.87)	.51 (.42-.62)
	Imaging only	.74 (.70-.80)	.08 (.06-.14)	.78 (.71-.83)	.51 (.42-.62)
	Imaging+Clinical Fusion	<b>.76 (.71-.81)</b>	.09 (.07-.13)	<b>.85 (.79-.89)</b>	<b>.54 (.46-.66)</b>
	Imaging+Clinical+Segmentation Fusion	.72 (.67-.79)	.08 (.06-.13)	.84 (.79-.88)	.53 (.44-.65)